The U.S. Food and Drug Administration (FDA) has approved Genentech’s intravenous drug Gazyva (Obinutuzumab) for the treatment of active lupus nephritis in adult patients receiving standard therapy.
Lupus nephritis is a severe autoimmune kidney pathology that affects more than 1.7 million people worldwide, particularly women of color and those of reproductive age. Approximately 33% of individuals with lupus nephritis are at risk of developing End-Stage Kidney Disease (ESKD), necessitating dialysis or kidney transplantation.
The FDA’s decision is based on the Phase II NOBILITY and Phase III REGENCY clinical trials. Specifically, in the pivotal REGENCY study, 46.4% of patients who received Gazyva along with standard therapy achieved a positive outcome (Complete Renal Response) after 76 weeks, compared to 33.1% of patients on placebo and standard therapy.
These results indicate a clinically significant improvement in disease control, which includes a reduction in proteinuria(decreased protein levels in the urine) and the possibility of reducing the dose of corticosteroids. Given the severe impact of lupus nephritis on renal function and quality of life, this new therapy makes it possible to preserve kidney function and delay/prevent the progression of renal failure.
Obinutuzumab is the third approved medication for lupus nephritis, following belimumab and voclosporin. It works by blocking CD20 on the surface of B cells, which ensures the reduction of the inflammatory process that causes kidney dysfunction. This decision points to a shift toward a more targeted form of lupus nephritis treatment, which ensures the optimization of clinical outcomes against a backdrop of safety monitoring.
The dosing regimen is comfortable for patients: after the initial loading dose, the time required for infusion is reduced, and the drug can be administered only twice a year.
Safety and Side Effects
Contraindications: Patients with a history of sensitivity (e.g., anaphylaxis or serum sickness) to obinutuzumab or any of its components should not be prescribed this medication.
Potential Serious Adverse Events: These events include infusion-related reactions, severe allergic reactions, serious infectious processes, leukopenia, thrombocytopenia, and disseminated intravascular coagulation (DIC).
Commonly Reported Adverse Events: Include upper respiratory tract infections, COVID-19 infection, urinary tract infections, bronchitis, pneumonia, and neutropenia.
Issues to Discuss with Your Doctor Before Starting Gazyva
Any relevant medical history.
Information about current or past infections, particularly the serological status of Hepatitis B or the presence of any active infectious process.
Information about recent or planned vaccinations; live vaccines are generally contraindicated during therapy and for a short period after its completion.
Plans for pregnancy or lactation, as Gazyva may potentially harm the fetus and is not recommended during breastfeeding.
Data regarding infusion-related reactions (both during the process and afterward), including signs of infection and allergies.
For effective management of potential serious adverse events, periodic laboratory blood tests are necessary throughout the entire therapeutic course to monitor leukocyte and platelet levels.
The approval of the drug represents a critical stage, as it provides a large portion of patients with lupus nephritis the opportunity to halt the progression of the disease and maximally preserve kidney function.
Source: Genentech
